September 18, 2013
The European Commission's Seventh Framework Program will award $801,360 throughout three years to scientific software company Qlucore to develop algorithms for use in personalizing hepatitis C treatment. The company will work on mathematical and statistical algorithms for integrating information from genetic, proteomic, and clinical research data to provide clinicians with a mobile application that could be used at the point of care. Pharmaceutical companies currently are developing new hepatitis C drugs that would lead to more genetic and clinical variables to evaluate for patients and create a need for tools that could assist clinicians in prescribing custom treatments for each patient.
09.16.2013; Ryan McBride
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|The Curious Case of M184V, Part 1|
|Inflammation in the Brain Continues Even With Undetectable Plasma Viral Load|
|Fat Gains Continue and Lean Mass Falls in Group on Long-Term HIV Therapy|
|This Week in HIV Research: Maintenance Therapy Regimen Containing Lamivudine May Be Viable Option|